Overview

Tipranavir in Patients With Progressive, Systemic HIV-1 Disease Who Have Failed or Are Intolerant to Currently Approved Treatments for HIV Infection

Status:
Approved for marketing
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
To provide early access to tipranavir and evaluate the safety and tolerance of tipranavir combined with low dose of ritonavir in patients with progressive, HIV-1 disease who have failed or are intolerant to currently approved treatments for HIV infection, who are unable to participate in another tipranavir controlled clinical trial and have an urgent need for anti-HIV treatment.
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Tipranavir